Trials / Completed
CompletedNCT03020992
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab Pegol | * pharmaceutical form: solution for infusion in prefilled syringe * concentration: 200 mg/mL * route of administration: subcutaneous |
Timeline
- Start date
- 2016-12-21
- Primary completion
- 2019-12-04
- Completion
- 2020-01-23
- First posted
- 2017-01-13
- Last updated
- 2021-02-09
- Results posted
- 2020-12-31
Locations
23 sites across 5 countries: Czechia, Germany, Netherlands, Poland, Spain
Source: ClinicalTrials.gov record NCT03020992. Inclusion in this directory is not an endorsement.